Drug and metabolite concentrations in tissues in relationship to tissue adverse findings: A review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 2, 2011, Pages 137-146

  Pellegatti, Mario ^a   Pagliarusco, Sabrina ^b  

^a GSK   (Italy)

^b Aptuit Inc   (United States)

Author keywords

adverse effects; drug distribution; long lasting metabolites; safety evaluation of metabolites; tissue accumulation; tissue metabolites; tissue specific concentrations

Indexed keywords

1,1 DICHLORO 2,2 BIS(4 CHLOROPHENYL)ETHYLENE; ABT 770; AMINOGLYCOSIDE; AMIODARONE; ARSENIC TRIOXIDE; CACODYLIC ACID; CASOPITANT; CHLORPHENOTANE; DRUG METABOLITE; FUMONISIN; MATRIX METALLOPROTEINASE INHIBITOR; MELANIN; NABILONE; UNCLASSIFIED DRUG;

CARDIOMYOPATHY; CONVULSION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG RETENTION; DRUG TISSUE LEVEL; HEART MUSCLE; HEART MUSCLE NECROSIS; HUMAN; LIPIDOSIS; NONHUMAN; OTOTOXICITY; REVIEW; TISSUE METABOLISM;

DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 79952138038     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.545053     Document Type: Review

References (65)

1. Solon EG. Autoradiography: high resolution molecular imaging in pharmaceutical discovery and development. Expert Opin Drug Discov 2007;2(4):503-14 (Pubitemid 47073075)
2. Shigematsu A, Motoji N, Hatori A, Satoh T. Progressive application of autoradiography in pharmacokinetic and metabolic studies for the development of new drugs. Regul Toxicol Pharmacol 1995;22:122-42
3. Braggio S, Montanari D, Rossi T, Ratti E. Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. Expert Opin Drug Discov 2010;5(7):609-18
4. Cazzola M, Blasi F, Terzano C, et al. Delivering antibacterials to the lungs: considerations for optimizing outcomes. Am J Respir Med 2002;1(4):261-72 (Pubitemid 37038945)
5. Palmer GM, Boruta RJ, Viglianti BL, et al. Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release 2010;142(3):457-64
6. Monro AM. Are routine tissue distribution studies justifiable for approval of human drugs? Drug Metab Dispos 1994;22(3):341 This and the following reference define the conceptual issues related to tissue distribution studies in a clear way.
7. Monro AM. Interspecies comparison in toxicology: the utility and futility of plasma concentrations of the test substance. Regul Toxicol Pharmacol 1990;12:137-60 This and the above reference define the conceptual issues related to tissue distribution studies in a clear way.
8. Brockman AH, Hatsis P, Paton M, Wu JT. Impact of differential recovery in bioanalysis: the example of bortezomib in whole blood. Anal Chem 2007;79:1599-603
9. Srinivas NR. Lack of stability of topotecan in heart tissue homogenates: is it an analytical dilemma or a real phenomenon? Biomed Chromatogr 2009;23:447-9
10. James CA, Breda M, Baratte S, et al. Analysis of drugs and metabolites in tissues and other solid matrices. Chromatogr Suppl 2004;59:S149-56
11. Drexler DM, Garrett TJ, Cantone JL, et al. Utility of imaging mass spectrometry (IMS) by matrix assisted laser desorption ionisation (MALDI) on an ion trap mass spectrometer in the analysis of drugs and metabolites in biological tissues. J Pharmacol Toxicol Methods 2007;55:279-88 (Pubitemid 46436524)
12. Solon EG, Schweitzer A, Stoeckli M, Prideaux B. Autoradiography, MALDI - MS, and SIMS-MS imaging in pharmaceutical discovery and development. AAPS J 2010;12(1):11-26
13. Sugiura Y, Setou M. Imaging mass spectrometry for visualization of drug and endogenous metabolite distribution: toward in situ pharmacometabolomes. J Neuroimmune Pharmacol 2010;5:31-43
14. Heeren RMA, Smith DF, Stauber J, et al. Imaging mass spectrometry: hype or hope? J Am Soc Mass Spectrom 2009;20(6):1006-14
15. Stumpf WE. Drug localisation and targeting with receptor microscopic autoradiography. J Pharmacol Toxicol Methods 2005;51:25-40 (Pubitemid 41556701)
16. Espie P, Tytgat D, Sargentini-Maier ML, et al. Physiologically based pharmacokinetics (PBPK). Drug Metab Rev 2009;41(3):391-407
17. Jones HM, Gardner IB, Watson KJ. Modelling and PBPK simulation in drug discovery. AAPS J 2009;11(1):155-66
18. Fenneteau F, Turgeon J, Couture L, et al. Assessing drug distribution in tissues expressing P-glycoprotein through physiologically based pharmacokinetic modelling: model structure and parameters determination. Theor Biol Med Model 2009;6(2):1-13
19. Lanao JM, Fraile MA. Drug tissue distribution: study methods and therapeutic implications. Curr Pharm Des 2005;11:3829-45 (Pubitemid 41632256)
20. Langer O, Muller M. Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab 2004;5:463-81 (Pubitemid 39534493)
21. Note for guidance for repeated dose tissue distribution studies. ICH topic S3B. CPMP/ICH/385/95. (1995). The European Agency for the Evaluation of Medicinal Products. Available from: http://www.ema.europa.eu/ema/index.jsp?curl= pages/regulation/general/general-content-000396.jsp&murl=menus/regulations/ regulations.jsp&mid=WC0b01ac058002956e
22. Lin JH. Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab 2006;7:39-65 A comprehensive review of the methods for studying tissue distribution including physiological basis and pharmacokinetic principles.
23. The International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-34
24. Thum T, Borlak J. Gene expression in distinct regions of the heart. Lancet 2000;355:979-82
25. Ahmad M, Ahmadi M, Nicholls J, Smith HJ. In-vitro metabolism of retinoic acid by different tissues from male rats. J Pharm Pharmacol 2000;52:511-15 (Pubitemid 30319154)
26. Brocks DR, Mehvar R. Rate and extent of drug accumulation after multiple dosing revisited. Clin Pharmacokinet 2010;49(7):421-38
27. Hebb JH, Caplan YH, Crooks CR, Mergner WJ. Blood and tissue concentrations of tricyclic antidepressant drugs in post-mortem cases: literature survey and a study of forty deaths. J Anal Toxicol 1982;6:209-16 (Pubitemid 12036245)
28. Drummer OH, Gerostamoulos J. Postmortem drug analysis: analytical and toxicological aspects. Ther Drug Monit 2002;24(2):199-209 (Pubitemid 34246549)
29. Drummer OH. Requirements for bioanalytical procedures in post-mortem toxicology. Anal Bioanal Chem 2007;388:1495-503 (Pubitemid 47150875)
30. Ferner RE. Post-mortem clinical pharmacology. Br J Clin Pharmacol 2008;66(4):430-43
31. Swanson JR, Jones GR, Krasselt W. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: a review of the literature and possible mechanisms. J Forensic Sci 1997;42(2):335-9 An interesting clinical example of the role of tissue concentration.
32. Eichler HG, Muller M. Drug distribution: the forgotten relative in clinical pharmacokinetics. Clin Pharmacokinet 1998;34(2):95-9 (Pubitemid 28077671)
33. Quartara L, Altamura M, Evangelista S, Maggi CA. Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 2009;18(12):1843-64
34. Herrstedt J, Apornwirat W, Shaharyar A, et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009;27:5363-9
35. Khojasteh A, Khojasteh A, Thornburg BG, Maher KR. Casopitant: a new warrior in the antiemetic crusade. Expert Opin Pharmacother 2009;10(8):1367-76
36. Miraglia L, Pagliarusco S, Bordini E, et al. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats and dogs. Drug Metab Dispos 2010;37:1876-91
37. Casartelli A, Lanzoni A, Comelli R, et al. A novel and integrated approach for the identification and characterisation of drug induced cardiac toxicity in the dog. Toxicol Pathol (In press) This and the reference below show an example of selective tissue accumulation of a metabolite, almost not detectable in plasma, which might be responsible for toxicity.
38. Pagliarusco S, Martinucci S, Bordini E, et al. Tissue distribution and characterization of drug related material in rats and dogs after repeat oral administration of casopitant. Drug Metab Dispos 2010: Published ahead of print October 26, 2010, doi: 10.1124/dmd.110.035063 This and the reference above show an example of selective tissue accumulation of a metabolite, almost not detectable in plasma, which might be responsible for toxicity.
39. Leblanc B, Jezequel S, Davies T, et al. Binding of drugs to eye melanin is not predictive of ocular toxicity. Regul Toxicol Pharmacol 1998;28:124-32 (Pubitemid 29076778)
40. Muhlebach S, Moor MJ, Wyss PA, Bickel MH. Kinetics of distribution and elimination of DDE in rats. Xenobiotica 1991;21(1):111-20
41. Rogan WJ, Chen A. Health risks and benefits of bis(4-chlorophenyl)-1,1,1- trichloroethane (DDT). Lancet 2005;366:763-73
42. Reasor MJ, Hastings KL, Ulrich RG. Drug- induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006;5(4):567-83 (Pubitemid 44468453)
43. Gaertner HG, Liomin G, Villumsen D, et al. Tissue metabolites of trifluoroperazine, fluphenazine, prochlorperazine and perphenazine. Kinetics in chronic treatment. Drug Metab Dispos 1975;3(6):437-43 An old article which showed very clearly the phenomenon of metabolite accumulation and long retention.
44. Breyer U, Gaertner HJ. The phenotiazines and structurally related drugs. Raven Press, New York; 1974. p. 167-73
45. Hein L, Lullmann-Rauch R, Mohr K. Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis. Xenobiotica 1990;20(11):1259-67
46. Lafuente-Lafuente C, Alvarez JC, Leenhardt A, et al. Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol 2009;67(5):511-19
47. Adams PC, Holt DW, Storey GCA, et al. Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. Circulation 1985;72(5):1064-75 (Pubitemid 16205408)
48. Gum RJ, Hickman D, Fagerland JA, et al. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem Pharmacol 2001;62:1661-73 (Pubitemid 34033653)
49. Kim KY, Lee YJ, Chung BC, et al. Relations between toxicity and altered tissue distribution and urinary excretion of nicotine, cotinine and hydroxycotinine after chronic oral administration of nicotine in rats. Drug Chem Toxicol 2010;33(2):166-72 An attempt to demonstrate the role of a metabolite in toxicity through a pharmacokinetic approach.
50. Sullivan HR, Hanasono GK, Miller WM, Wood PG. Species specificity in the metabolism of nabilone. Relationship between toxicity and metabolic routes. Xenobiotica 1987;17(4):459-68
51. Riley RT, Voss KA. Differential sensitivity of rat kidney and liver to fumonisin toxicity: organ- specific differences in toxin accumulation and sphingoid base metabolism. Toxicol Sci 2006;92(1):335-45
52. Hawkins E. Ototoxic mechanisms: a working hypothesis. Audiology 1973;12(5-6):383-93
53. Kitasako I, Yokota M, Inouye S, Igarashi M. Comparative ototoxicity of ribostamycin, dactimicin, dibekacin, kanamycin, amikacin, tobramycin, gentamicin, sisomicin and netilmicin in the inner ear of guinea pigs. Chemother 1990;36(2):155-68 (Pubitemid 20079280)
54. Dulon D, Aran JM, Zajic G, Schacht J. Comparative uptake of gentamicin, netilmicin and amikacin in the guinea pig cochlea and vestibule. Antimicrob Agents Chemother 1986;30(1):96-100 (Pubitemid 16097382)
55. Lin CJ, Wu MH, Hsueh YM, et al. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue selective. Cancer Chemother Pharmacol 2005;55:170-8 A clear example of tissue selective accumulation of metabolites and of different metabolic profile between plasma and tissues.
56. Park BK, Srivastava A, Maggs JL, et al. Role of reactive metabolites in drug-induced hepatotoxicity. Handb Exp Pharmacol 2010;196:165-94
57. Kumar S, Mitra K, Kassahun K, Baillie TA. Approaches for minimizing metabolic activation of new drug candidates in drug discovery. Handb Exp Pharmacol 2010;196:511-44
58. Oitate M, Hirota T, Takahashi M, et al. Mechanism for covalent binding of rofecoxib to elastin of rat aorta. J Pharmacol Exp Ther 2007;320(3):1195-203 (Pubitemid 46294044)
59. Prueksaritanont T, Lin JH, Baillie TA. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol Appl Pharmacol 2006;217:143-52 A clear description of all the potential issues in the safety evaluation of metabolites.
60. Williams RT. Detoxication mechanisms. John Wiley and Sons, Inc., New York; 1947
61. Andersen ME, Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol Sci 2009;107(2):324-30
62. Vonderfecht SL, Stone ML, Eversole RR, et al. Myopathy related to administration of cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol 2004;32:318-25 (Pubitemid 38692002)
63. Dear GJ, Roberts AD, Beaumont C, North S. Evaluation of preparative high performance liquid chromatography and cryoprobe- nuclear magnetic resonance spectroscopy for the early quantitative estimation of drug metabolites in human plasma. J Chromatogr B 2008;876:182-90
64. Espina R, Yu L, Wang J, et al. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem Res Toxicol 2009;22:299-310
65. Walker R. The significance of excursions above the ADI: duration in relation to pivotal studies. Regul Toxicol Pharmacol 1999;30:S114-18